AI Tools for Beginners

I help non-technical folks build apps with AI. Over 120,000 subscribers

Join readers from OpenAI, Microsoft and DeepMind, to get hype-free updates on the arrival of smarter-than-human AI. Totally free, with premium options available.

Superintelligence is a newsletter to guide you in surviving & thriving in the age of Al.Founded by & written daily by Kim we cover all of the latest Al news &product releases, in addition to deep dives in:

Daily newsletters from the cutting edge of AI, including breaking news, strategy,product breakdowns, and thought pieces Over 50,000 subscribers

In-depth coverage of humanoid robot developments, including agility feats, AI integration, and real-world applications like combat simulations or factory deployment. Features expert analysis from engineers.

Explores AI's role in robotics, with spotlights on humanoid breakthroughs (e.g., single-model training for movements) and broader implications like workforce integration. Includes reader Q&A on robot 'breakthroughs.'

Daily/weekly robotics news digest, heavy on humanoid updates from global players, including Chinese firms like Unitree, with analysis on hardware, software, and events like CES or UFC demos.

AI and robotics-focused, covering humanoid 'revolutions' from bartenders to surgical aides, with exclusive interviews and trends like Tesla's Optimus scaling.

A newsletter co-hosted by the Wyss Institute at Harvard University, focusing on the intersection of AI, biology, and healthcare to transform medicine, with emphasis on AI-driven drug discovery and accelerating life-saving therapies.

Daily insights into health care innovations, including AI's role in drug discovery, repurposing existing drugs for rare diseases, and accelerating treatments for conditions like idiopathic pulmonary fibrosis and ALS.

Top stories in biotechnology, drug discovery, and pharma, highlighting AI-enabled milestones like clinical trials for AI-discovered drugs targeting idiopathic pulmonary fibrosis and regulatory challenges in AI therapeutics.

Breaking news and breakthroughs on AI applications in healthcare, covering precision medicine, AI-discovered drugs for cancer and neurological disorders, and accelerated timelines in psychiatric drug design.

Absci's AI-generated drug ABS-201 targets the telogen (shedding) phase directly, bypassing initial hair loss from minoxidil. It reactivates follicles and repigments hair, with preclinical data showing reversal in balding models. Phase 1 human trials launched mid-2025; could hit market by 2028.